Cost-effective utilization of CK-MB mass and activity assays - Evaluation of patients with chest pain in the emergency department

Citation
Lv. Rao et al., Cost-effective utilization of CK-MB mass and activity assays - Evaluation of patients with chest pain in the emergency department, LAB MED, 30(4), 1999, pp. 271-275
Citations number
18
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology
Journal title
LABORATORY MEDICINE
ISSN journal
00075027 → ACNP
Volume
30
Issue
4
Year of publication
1999
Pages
271 - 275
Database
ISI
SICI code
0007-5027(199904)30:4<271:CUOCMA>2.0.ZU;2-M
Abstract
Effective use of creatine kinase M and B isoform (CK-MB) test results for t he diagnosis or exclusion of acute myocardial infarction (AMI) requires rep eated analyses at defined intervals after the onset of chest pain. An incre ase in serum CK-MB is evaluated relative to typical angina-like chest pain of at least 30 minutes duration and electrocardiographic changes per World Health Organization (WHO) standards, Two or more of the three findings must be abnormal for the diagnosis of AMI. We assessed the appropriateness clin ical usefulness) and cost-effectiveness of CK-MB mass and activity levels i n the care of patients with complaints of chest pain seen in our emergency department. The total CK and CK-MB (mass and activity) results for 860 pati ents during 2 months in 1995 were reviewed retrospectively relative to the discharge diagnosis. According to the discharge diagnoses based on the WHO diagnostic criteria for AMI only 54 patients (6.3%) had acute myocardial in farction. Three or more CK-MB tests (mass and activity measurements) were p erformed in 60.5% of patients, and only one test was performed in the remai ning 39.5%. Abnormal CK-MB mass or activity was determined with the followi ng criteria: Protocol 1: CK-MB mass >5 ng/mL, total CK >194 U/L index >2.5% ; Protocol 2: CK-MB activity >16 U/L, total CI( >65 U/L, index >5%; Protoco l 3: CK-MB activity >10 U/L, total CK >65 U/L, index >2.2%. Based on these criteria, CK-MB mass and activity protocols gave positive predictive values of 38.2%, 36.1%, and 35.4% for protocols 1, 2 and 3, respectively The nega tive predictive value was 99% for CK MB mass (Protocol 1), and 98% and 98.9 % for CK-MB activity(Protocols 2 and 3). These results indicate that both C K-MB mass and activity protocols have equivalent clinical usefulness. Howev er, given the technologic limitation of two platforms for Protocol 1 vs one assay platform for Protocols 2 and 3, the CK-MB activity protocol is more cost-effective for patient testing in the emergency department laboratory.